Thrombectomy Devices Market

Global Thrombectomy Devices Market:

The global thrombectomy devices market size reached USD 1.41 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 2.13 Billion by 2033, exhibiting a growth rate (CAGR) of 4.48% during 2025-2033. North America currently dominates the global market, owing to the rising incidences of venous thromboembolism (VTE) among the geriatric population. Moreover, rising preferences for thrombectomy devices by surgeons to perform image-guided surgeries and continuous improvements in healthcare infrastructures are primarily propelling the market.

Global Thrombectomy Devices Market Analysis:

• Major Market Drivers: The increasing prevalence of chronic diseases, owing to the growing number of individuals who consume alcohol, is one of the key factors stimulating the thrombectomy devices market growth. Furthermore, favorable medical reimbursements by government bodies are also acting as significant growth-inducing factors.
• Key Market Trends: The elevating investments in R&D activities by leading players to introduce technologically advanced thrombectomy devices are among the emerging trends fueling the thrombectomy devices market demand. Moreover, the rising inclination among individuals towards minimally invasive (MI) procedures will continue to stimulate the market over the forecasted period.
• Geographical Trends: According to the thrombectomy devices market overview, North America currently dominates the global market, owing to the rising incidences of venous thromboembolism (VTE) among the geriatric population. Apart from this, extensive public and private funding initiatives by government bodies, especially in the U.S., to create awareness among individuals regarding advanced thromboembolism devices are positively influencing the thrombectomy devices market share in North America.
• Competitive Landscape: As per the thrombectomy devices market research, some of the leading players across the global market include Acandis GmbH, AngioDynamics, Argon Medical Devices, Boston Scientific Corporation, Inari Medical, Inc., Inquis Medical, LeMaitre, Medical Devices Business Services, Inc., Medtronic, Penumbra, Inc., Stryker Corporation, Teleflex Incorporated, and Terumo Corporation, among many others.
• Challenges and Opportunities: One of the primary challenges hampering the thrombectomy devices market revenue includes complex approval processes by regulatory bodies, including the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). Moreover, ensuring compliance with these regulations can be time-consuming and costly, which can hinder the thrombectomy devices market price. However, extensive investments in R&D activities across the healthcare sector and favorable reimbursement policies by government bodies are expected to drive the thrombectomy devices market value over the forecasted period.

Global Thrombectomy Devices Market Trends:

Increasing Incidence of Cardiovascular and Cerebrovascular Diseases

The market for thrombectomy devices is growing steadily as the incidence of cardiovascular and cerebrovascular diseases is increasing globally. Ischemic stroke, deep vein thrombosis, and pulmonary embolism are on the rise because of lifestyle changes, aging populations, and increased obesity, diabetes, and hypertension. Since these conditions continue to be major causes of morbidity and mortality, physicians are increasingly using cutting-edge thrombectomy solutions for efficient clot evacuation and reinstatement of blood flow. Increasing disease burden is further driving the need for less invasive interventions that enhance survival and minimize complications. Governments and healthcare organizations are also highlighting early diagnosis and treatment strategies, which is further cementing the use of thrombectomy procedures. Along with this, health awareness campaigns and public health programs are raising stroke awareness, causing quicker hospitalizations and higher use of thrombectomy devices. In India, a stroke occurs every 20 seconds, prompting the Indian Stroke Association (ISA) to launch a national awareness campaign named “Brain Stroke—Time to Act” in 2025. Initiated in collaboration with the Indian Association of Physicians, CGAP Raipur Chapter, and SEMI, the initiative combines professional training with community engagement to enhance swift recognition and treatment.

Innovation in Thrombectomy Technologies

The market is growing at a huge rate because ongoing innovation in thrombectomy technologies is enhancing procedural safety and clinical results. Manufacturers are creating new devices that enable quicker, more secure, and more effective clot removal, especially for ischemic stroke intervention. Innovations like aspiration thrombectomy systems, stent retrievers, and new-generation mechanical devices are giving doctors more precision and versatility in procedures. In addition, combination of advanced imaging technologies and real-time navigation systems is allowing for more precise targeting of clots, lowering the risk of damage to vessels and procedural complications. These technology advancements are also reducing procedure durations and improving patient recovery rates, thereby making thrombectomy an increasingly popular treatment option. Medical device manufacturers are spending heavily on research and development, with a constant flow of product approvals and releases in major markets. Thus, the industry is enjoying sustained clinical adoption and increasing physician confidence in sophisticated thrombectomy technology. In 2025, Inari Medical, a part of Stryker, declared the launch of its next-generation InThrill thrombectomy system. It is a specially designed, compact vessel and arteriovenous (AV) access thrombectomy system intended to provide quick, complete luminal clot extraction.

Increasing Use of Minimally Invasive Interventions

The market is growing with hospitals and clinics increasingly opting for minimally invasive thrombectomy procedures instead of traditional surgical techniques. Minimally invasive techniques are providing immense benefits in the form of quicker recovery, shorter hospitalization, fewer complications, and enhanced patient comfort. With patients and medical professionals becoming increasingly aware of these advantages, demand for thrombectomy devices is consistently rising. Surgeons and interventional radiologists are increasingly opting for minimally invasive methods, particularly for time-sensitive conditions like ischemic stroke, wherein quicker intervention is responsible for preventing permanent disability. The global healthcare sector is also focusing on cost-effectiveness, and minimally invasive treatments are lowering aggregate treatment costs by reducing intensive care needs. Moreover, reimbursement guidelines in numerous countries are facilitating the transition towards minimally invasive thrombectomy, further supporting the market growth. IMARC group predicts that the global minimally invasive surgery market is projected to attain USD 94.9 Billion by 2033.

Thrombectomy Devices Market Growth Drivers:

Growing Geriatric Population

The geriatric population is driving the thrombectomy devices market with its growing demands, as this population group is highly vulnerable to stroke and thrombotic disorders. As the global population is ageing at a rapid rate, the number of geriatric patients needing clot extraction procedures is going up steadily. Ageing populations are suffering more from vascular illnesses as a result of the natural changes in blood vessels, comorbid conditions like diabetes and hypertension, and decreased physical activity. This growing population trend is generating steady demand for successful thrombectomy devices that can treat age-related complications safely and effectively. Healthcare institutions globally are focusing more on enhancing stroke treatment and cardiovascular care for aged patients, and this is facilitating investments in cutting-edge interventional treatments. Additionally, since life expectancy is rising in both developed and developing economies, the number of aged patients going for treatment is progressively increasing. This factor is increasingly leading to market growth, guaranteeing sustained demand for thrombectomy treatments across the globe.

Rising Investments in Healthcare Infrastructure

The market is progressing with governments, private health providers, and investors escalating spending on developing healthcare infrastructure. Most nations are increasing hospital networks, enhancing emergency care centers, and furnishing medical centers with advanced interventional devices such as thrombectomy systems. This is especially significant in stroke management, where intervention needs to be quick. Investments are directed towards enhancing access to advanced treatment technologies in urban and rural areas alike, thus expanding the patient population undergoing thrombectomy procedures. Rising economies are also witnessing robust increases in healthcare expenditure, driven by government reforms and public-private collaborations. Educational programs for physicians and interventionalists are being widened to enhance procedural skill, further facilitating device adoption. While healthcare infrastructure continues to improve so that complex vascular emergencies are being tackled more effectively, the need for thrombectomy devices is increasingly robust.

Positive Reimbursement Policies and Regulation Approvals

The market for thrombectomy devices is growing with positive reimbursement policies and favorable regulatory approvals that are driving increased access to sophisticated treatments. In some mature economies, reimbursement schemes are paying for thrombectomy treatments for stroke and other vascular disorders, lowering costs for patients. That is prompting hospitals to embrace thrombectomy devices more widely. Regulatory bodies are at the same time expediting clearances for new thrombectomy technologies, enabling quicker market introduction for new offerings. The clearance of new-generation aspiration catheters and stent retrievers is augmenting treatment options for clinicians and enhancing patient outcomes. The positive policies are also encouraging manufacturers to diversify products and enhance clinical trials to prove safety and efficacy. In emerging markets, governments are slowly adopting reimbursement reforms, which is further enhancing the affordability of treatment. As reimbursement assistance and regulatory adaptability are bolstering, thrombectomy devices increasingly become available, ultimately driving global market penetration.

Global Thrombectomy Devices Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2025-2033. Our report has categorized the market based on the product type, application, and end user. 

Breakup by Product Type:

• Aspiration Thrombectomy Devices
• Mechanical Thrombectomy Devices
• Ultrasonic Thrombectomy Devices
• Others

Currently, mechanical thrombectomy devices account for the majority of the global market share

The report has provided a detailed breakup and analysis of the market based on the product type. This includes aspiration thrombectomy devices, mechanical thrombectomy devices, ultrasonic thrombectomy devices, and others. According to the report, mechanical thrombectomy devices accounted for the largest market share.

The increasing prevalence of ischemic strokes is primarily stimulating the demand for mechanical thrombectomy devices, thereby bolstering the market growth in this segmentation. For example, NeuroVasv introduced the ENVI-SR Mechanical Thrombectomy System (ENVI-SR), a stent-retriever for the removal of blood clots in patients with acute ischemic stroke. Moreover, mechanical thrombectomy devices significantly minimize stroke-related disabilities in patients when used with tPA and other medical treatments. The elevating demand for minimally invasive surgical procedures and favorable reimbursement policies by government bodies for neurovascular and cardiovascular procedures are anticipated to drive the segment's growth over the foreseeable future.

Breakup by Application:

• Cardiovascular
• Neurovascular
• Peripheral Vascular

Among these, neurovascular currently holds the largest market share

The report has provided a detailed breakup and analysis of the market based on the application. This includes cardiovascular, neurovascular, and peripheral vascular. According to the report, neurovascular accounted for the largest market share. 

The growing awareness among individuals about neurological conditions, including stroke, is propelling the adoption of thrombectomy devices in neurovascular processes. Furthermore, the US Food and Drug Administration (USFDA) has been collaborating with leading manufacturers and professional societies, such as the National Institutes of Health (NIH) and the NeuroPoint Alliance, to help in developing robust registries that can also be used to generate data for premarket application and post-market surveillance. Besides this, key players are also introducing novel thrombectomy devices to treat acute ischemic stroke (AIS) and its associated symptoms, thereby positively influencing the market growth in this segmentation. For example, in January 2023, Infinity Neuro announced CE Mark approval for its Inspira aspiration catheters.

Breakup by End User:

• Hospitals and Clinics
• Ambulatory Surgical Centers
• Others

Hospitals and clinics exhibit a clear dominance in the market

The report has provided a detailed breakup and analysis of the market based on the end user. This includes hospitals and clinics, ambulatory surgical centers, and others. According to the report, hospitals and clinics accounted for the largest market share. 

Hospitals and clinics are preferred by patients as compared to emergency clinics, due to improved healthcare facilities and the easy availability of advanced equipment. Besides this, the rising incidence of acute ischemic diseases and the elevating awareness among individuals regarding thrombectomy devices are some of the primary factors driving the segment's growth. Additionally, specialized departments, operating rooms, advanced labs, etc., in hospitals offer an ideal setting for clot management procedures.

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

North America exhibits a clear dominance in the market

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

The rising number of individuals suffering from heart attack and cardiac arrest, owing to their hectic schedules and sedentary lifestyles, is primarily driving the thrombectomy devices market in North America. For example, in 2022, the Centre for Disease Control and Prevention (CDC) reported that 805,000 individuals had a heart attack in the United States. Similarly, in 2022, an article published in the National Library of Medicine reported that in the United States, about 610,000 people die of heart disease every year. Consequently, the elevating occurrence of chronic diseases is inflating the need for thrombectomy devices, which is acting as another significant growth-inducing factor. Moreover, favorable reimbursement scenarios for these devices and the expanding healthcare industry are positively influencing the regional market. For example, in August 2021, Stryker Neurovascular received the regulatory United States Food and Drug Administration (USFDA) approval for the Trevo NXT Pro Vue Retriever, a class II medical equipment generally classified as a neurovascular mechanical thrombectomy device for acute ischemic stroke.

Competitive Landscape:

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

• Acandis GmbH
• AngioDynamics
• Argon Medical Devices
• Boston Scientific Corporation
• Inari Medical, Inc.
• Inquis Medical
• LeMaitre
• Medical Devices Business Services, Inc.
• Medtronic
• Penumbra, Inc.
• Stryker Corporation
• Teleflex Incorporated
• Terumo Corporation

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

Global Thrombectomy Devices Market News:

• June 2025: With a distribution deal established and a potential to purchase Contego Medical, Medtronic's peripheral vascular division began 2025 with increased investment in the carotid artery stenting (CAS) sector. The action indicated the beginning of a potentially transformative phase in various business units of the division, featuring new product offerings and enhancements to legacy platforms in carotid and venous disease, dialysis access, and peripheral artery disease (PAD), including one significant exit.
• May 2025: In a major advancement for India's medtech innovation sector, the Technology Development Board (TDB), part of the Department of Science and Technology (DST), has provided financial assistance to M/s S3V Vascular Technologies Limited, Mysuru, for their initiative named “Integrated Manufacturing of Mechanical Thrombectomy Kit for Treatment of Acute Ischemic Stroke.” The board has approved support for this groundbreaking project focused on revolutionizing stroke care via local innovation.
• April 2025: Anaconda Biomed, S.L., a medical technology firm creating advanced neurothrombectomy devices, announced the enrollment and treatment of the initial U.S. patient in its ATHENA clinical trial conducted by Shahram Majidi, MD, Associate Professor of Neurosurgery, Neurology, and Radiology at Icahn School of Medicine at Mount Sinai, New York. ATHENA is a worldwide, randomized pivotal study involving 327 patients to assess the safety and efficacy of Anaconda’s proprietary ANA Funnel Catheter™.
• March 2024: L&T chairman emeritus A M Naik, investors, such as Madhusudan Kela and Utpal Sheth, along with other high net worth individuals, have invested in medical devices firm S3V Vascular Technologies Ltd to help it set up a facility that will develop neurovascular devices to treat strokes.
• February 2024: Endovascular Engineering Inc., one of the key medical device companies to advance clot removal technologies for venous thromboembolism (VTE), announced the enrollment and treatment of the first patient in the pivotal phase of its ENGULF US clinical trial. This IDE trial will further evaluate the efficacy and safety of the Hēlo PE thrombectomy system, a novel technology, for treating pulmonary embolism (PE).
• January 2024: Surmodics, Inc., one of the leading providers of medical devices in vitro diagnostic technologies, announced the early clinical use of the company’s Pounce LP (Low Profile) thrombectomy system. The Pounce LP thrombectomy system, which received U.S. Food and Drug Administration (FDA) clearance in June 2023, is currently in limited market evaluation (LME), with a full commercial launch planned following the completion of the LME.

Thrombectomy Devices Market Report Scope:

Key Benefits for Stakeholders:

• IMARC’s report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the thrombectomy devices market from 2019-2033.
• The research study provides the latest information on the market drivers, challenges, and opportunities in the global thrombectomy devices market.
• The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
• Porter's five forces analysis assist stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the thrombectomy devices industry and its attractiveness.
• Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.